Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Price-Fixing Litigation Presses On With 'Overarching Conspiracy' Claims Intact

Executive Summary

Judge allows plaintiffs to argue attendance at trade association meetings and job-hopping show scheme to fix drug prices; confidentiality of attorney communication is in dispute.

You may also be interested in...



Insurance Giant Sues Again On US Pricing

Mylan, Sandoz and Teva, as well as Apotex, Aurobindo, Dr Reddy’s and Lupin, are among the companies accused of price-fixing in the US in an action brought by US insurance giant Humana.

Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe; Will Others Follow?

Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.

Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing

Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel